BBNX Stock: Price, Earnings History and SEC Filings
Beta Bionics, Inc. (BBNX) last traded at $16.75, down 4.72% on the latest session and down 11.7% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $-0.52 against an analyst estimate of $-0.53, a beat of 1.9%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BBNX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 27, 2026 | $-0.52 | $-0.53 | +1.89% |
| Jun 2026 | Jul 29, 2026 | $-0.53 | $-0.62 | +14.52% |
| Mar 2026 | Apr 21, 2026 | $-0.49 | $-0.53 | +7.55% |
| Dec 2025 | Feb 17, 2026 | $-0.30 | $-0.42 | +28.57% |
BBNX beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How BBNX reacts to earnings
Across its last 8 earnings releases, BBNX moved 14.2% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-27 | After close | -16.55% |
| 2026-07-29 | After close | -5.93% |
| 2026-04-21 | After close | -0.57% |
| 2026-02-17 | After close | -2.58% |
| 2026-01-08 | After close | -37.04% |
| 2025-10-28 | After close | +10.34% |
| 2025-07-29 | After close | +14.32% |
| 2025-05-06 | After close | +26.61% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
BBNX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $100M | -$73M | -$56M | -73.0% | $-1.81 |
| 2024 | $65M | -$55M | -$52M | -84.1% | $-8.60 |
| 2023 | $12M | -$44M | -$33M | -367.6% | $-8.31 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for BBNX
- 10-Q · Oct 27, 2026
- 8-K · Oct 27, 2026Results of operations, Financial statements and exhibits
- 8-K · Sep 17, 2026Other events, Financial statements and exhibits
- 424B5 · Sep 17, 2026
- 424B5 · Sep 16, 2026
- 8-K · Sep 15, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-Q · Jul 29, 2026
- 8-K · Jul 29, 2026Results of operations, Financial statements and exhibits
- 8-K · May 22, 2026Shareholder vote
- 8-K · May 21, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
Insider filing activity
BBNX insiders filed 15 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
BBNX news
- Beta Bionics, Inc. Q3 2026 Earnings Call SummaryOct 28, 2026 · app.moby.co
- Beta Bionics (BBNX) Q3 2026 Earnings Call TranscriptOct 28, 2026 · fool.com
- Beta Bionics Q3 Earnings Call HighlightsOct 28, 2026 · marketbeat.com
- Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue EstimatesOct 27, 2026 · finance.yahoo.com
- Beta Bionics Announces Third Quarter 2026 Financial Results and Updates Full Year 2026 GuidanceOct 27, 2026 · finance.yahoo.com
- IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should KnowOct 22, 2026 · finance.yahoo.com
- Beta Bionics, Inc. (BBNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Oct 20, 2026 · finance.yahoo.com
About Beta Bionics, Inc.
Beta Bionics, Inc. (BBNX) is a US-listed public company on Nasdaq. The SEC classifies its business as Surgical & Medical Instruments & Apparatus. It is incorporated in DE. Its fiscal year ends in December.